Bladder Cancer Clinical Trial

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Summary

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.

View Full Description

Full Description

The study includes a dose escalation phase (phase Ib) and an expansion phase (phase IIb).

In the phase Ib, patients will be treated with intravesical N-803 in combination with BCG. The purpose of the phase Ib portion of the study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of N-803 and determine the Recommended Dose (RD) level of N-803 in combination with BCG for the phase IIb expansion.

In the phase IIb expansion, patients will be randomized to receive either intravesical N-803 in combination with BCG or BCG alone. Patients will be enrolled into one of two study cohorts (Cohort A and Cohort B). These will be two independent study cohorts, evaluated separately for treatment efficacy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).

Cohort A: Histologically confirmed CIS (with or without Ta/T1 disease); Cohort B: Histologically confirmed high-grade papillary disease (Ta/T1 only).
Patients are eligible if the diagnostic biopsy was done within 3 months of treatment start and a cystoscopy demonstrating no resectable disease was done within 6 calendar weeks (inclusive of 48 days) of treatment start (residual CIS is acceptable; patients with T1 disease must undergo repeat resection if muscularis propria is not present in each biopsy sample). Patients with high-grade Ta and/or T1 disease should have complete resection before study treatment.
Upper tract imaging within 6 months prior to study entry must not be suspicious for upper tract malignancy.
Currently eligible for intravesical BCG therapy.
Age ≥ 18 years.
Performance status: ECOG performance status of 0, 1, or 2.

Laboratory tests performed within 21 days of treatment start:

Absolute neutrophil count (AGC/ANC) ≥ 1,000/µL
Platelets ≥ 100,000/µL [Patients may be transfused to meet this requirement]
Hemoglobin ≥ 8 g/dL [Patients may be transfused to meet this requirement]
Calculated glomerular filtration rate (GFR*) >40 mL/min or Serum creatinine ≤ 1.5 x ULN
Total bilirubin ≤ 2.0 X ULN
AST, ALT, ALP ≤ 3.0 X ULN
Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction. PFT > 50% FEV1 if clinically indicated by the investigator.
Negative serum pregnancy test if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).
Female participants of childbearing potential must adhere to using a medically accepted method of birth control prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study.

Provide signed informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations.

using the following Cockcroft-Gault equation to calculate the eGFR for this study: eGFR in mL/min = {(140-age in years) x (weight in kg) x F}/(serum creatinine in mg/dL x 72) Where F =1 if male; and 0.85 if female

Exclusion Criteria

Prior BCG treatment or known hypersensitivity to BCG. Patients who have received more than a single-dose post-operative treatment of mitomycin-C or gemcitabine following the most recent screening TURBT/biopsy are excluded.
Concurrent use of other investigational agents (not including FDA-authorized drugs for the prevention and treatment of COVID-19).
History of or evidence of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer or any other cancer within the past 5 years, except: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage 1 or 2 cancer from which the patient is currently in complete remission, or stable prostate cancer (under active surveillance or hormone control).
Symptomatic congestive heart failure (CHF), NYHA (New York Heart Association) Class III or IV or other clinical signs of severe cardiac dysfunction.
Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry.
History or evidence of uncontrollable CNS disease.
Known HIV-positive.
Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
Concurrent febrile illness, active urinary tract infection, active tuberculosis, a history of hypotension or anaphylactic reactions.
Ongoing chronic systemic steroid therapy required (>10 mg oral prednisone daily or equivalent).
Women who are pregnant or nursing. Female patients of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.
Psychiatric illness/social situations that would limit compliance with study requirements.
Other illness that in the opinion of the investigator would exclude the patient from participating in this study.

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

596

Study ID:

NCT02138734

Recruitment Status:

Recruiting

Sponsor:

ImmunityBio, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 24 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
Alaska Clinical Research Center
Anchorage Alaska, 99503, United States
Arkansas Urology
Little Rock Arkansas, 72211, United States
Hoag Cancer Center
Irvine California, 92618, United States More Info
Leila Andres
Contact
[email protected]
Jeffrey Bassett, MD, MPH
Principal Investigator
UCLA Department of Urology
Los Angeles California, 90095, United States More Info
Ankush Sachdeva
Contact
310-794-3512
[email protected]
Sara Rodriguez
Contact
[email protected]
Karim Chamie, MD
Principal Investigator
University of California, Davis
Sacramento California, 95817, United States
Skyline Sherman Oaks
Sherman Oaks California, 91411, United States
Skyline Urology
Torrance California, 90505, United States
Eastern Connecticut Hematology & Oncology Associates
Norwich Connecticut, 06360, United States
Clinical Research Center of Florida
Pompano Beach Florida, 33060, United States
Moffitt Cancer Center
Tampa Florida, 33612, United States More Info
Austin Lannon
Contact
[email protected]
Wade Sexton, MD
Principal Investigator
University of Hawaii Cancer Center
Honolulu Hawaii, 96813, United States
Kansas University Medical Center
Westwood Kansas, 66205, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Adult & Pediatric Urology
Omaha Nebraska, 68114, United States
Dartmouth-Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States More Info
Quinn Coughlin
Contact
[email protected]
Einar F Sverrisson, MB
Principal Investigator
Urology Group of New Mexico (AccumetRx Clinical Research)
Albuquerque New Mexico, 87109, United States
Winthrop University Hospital
Mineola New York, 11501, United States More Info
Maryum Ghafary
Contact
Aaron E Katz, MD
Principal Investigator
Manhattan Medical Research
New York New York, 10016, United States More Info
Luis Leanez
Contact
917-409-3919
[email protected]
Premier Medical Group of the Hudson Valley
Poughkeepsie New York, 12601, United States More Info
Lisa Gray
Contact
845-437-5000
[email protected]
Evan Goldfischer, MD
Principal Investigator
University of North Carolina Chapel Hill
Chapel Hill North Carolina, 27278, United States More Info
Chris Paterno, BSN, RN
Contact
919-537-3505
[email protected]
Marc Bjurlin, DO
Principal Investigator
Associated Urologists of North Carolina
Raleigh North Carolina, 27612, United States More Info
Kip Moffett
Contact
[email protected]
Mark Jalkut, MD
Principal Investigator
Virginia Urology
Richmond Virginia, 23235, United States More Info
Brittany Quigley
Contact
[email protected]
Eugene Kramolowsky, MD
Principal Investigator
University of Washington School of Medicine
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

596

Study ID:

NCT02138734

Recruitment Status:

Recruiting

Sponsor:


ImmunityBio, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.